Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 21 - 30 out of 46

AMIA Comments on CMS Innovation Center RFI

November 21, 2017

In response to a CMS Innovation Center request for information (RFI) on its potential new direction, AMIA offered several suggestions focusing on the interdependency of payment and delivery reforms, supported by health IT and health informatics. AMIA suggested additional guiding principles with which to approach new Innovation Center model design […]

AMIA Supports VA Telehealth Expansion Proposal

November 2, 2017

AMIA provided comments to a VA proposed rule that would allow its providers to furnish telehealth services, regardless of the state or location where they or the beneficiary is physically located. AMIA supported the proposal, while emphasizing that any telehealth applications use nationally recognized health IT standards and enable use […]

AMIA Comments Regarding FDA’s Medical Device User Fee Agreement Letter (MDUFA IV)

November 2, 2016

In comments submitted to the FDA, AMIA voiced supported for several aspects of MDUFA IV meant to enhance use of consensus standards; develop patient engagement strategies and improve the science of patient input; utilize real world evidence (RWE) to improve regulatory decision-making; and development of a policy framework for Digital […]

AMIA Comments Regarding FDA PDUFA VI Commitment Letter

August 16, 2016

In conjunction with a public meeting held by the FDA August 15, 2016, AMIA submitted public comments supporting the direction of the its Prescription Drug User Fee Agreement Commitment Letter.  Specifically, AMIA supports FDA’s work to utilize Real World Evidence in regulatory decision-making, incorporating the patient’s voice in drug development […]

AMIA Comments on NIST Usability Guidance

November 10, 2011

AMIA acknowledged NIST’s efforts to highlight the importance of usability testing for electronic health records (EHRs) through its issuance of the proposed guidance. AMIA expressed concerns about several aspects of the draft guidance including the following: a limited and narrow identification of EHR users; the need to consider more comprehensive […]